A 46-year-old manwith hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment. During the paralytic episode, serum potassium levels were reduced, and serum chloride and insulin levels were increased. The data suggested proximal renal tubular acidosis due to ACZ. We determined arterial-venous concentrations of potassium, insulin and glucose across the forearm. Venous potassium levels were markedly reduced. ACZis thought to potentiate potassium uptake into muscles. Hyperinsulinemia and DMcould contribute to ACZ-induced exacerbation in our patient. We should pay more attention to ACZ-treated HypoPPpatients with hyperinsulinemia and DM. (Internal Medicine 41: 743-745, 2002) 
Introduction
Hypokalemic periodic paralysis (HypoPP) is characterized by attacks of transient muscle weakness in the extremities. Acetazolamide (ACL), a carbonic anhydrase inhibitor, is commonly used for the preventation of HypoPPattacks ( 1 , 2) . However, several reports suggest that this agent exacerbates attacks of muscle weakness in patients with HypoPP (3) (4) (5) or paramyotonia congenita (6) . The mechanism of these harmful effects remains unknown.Wereport a unique patient with HypoPP and diabetes mellitus (DM) with ACZ-induced paralytic attacks and proximal renal tubular acidosis. In our patient, we analyzed arterial-venous concentrations of potassium, insulin and glucose across the forearm at paralytic and recovery periods. Wediscuss clinical hallmarks and possible mechanismofACZinduced HypoPPattacks.
Case Report
A 46-year-old man was diagnosed as HypoPP at the age of 28 years. When he received potassium (8 to 24 mEq/day) and spironolactone (25 mg/day) from 1996 to 1999, he had attacks of weaknessa few times per month. Previous data showedthat serum potassium levels were 3.8 to 4.2 mEq// during non-attack periods. Treatment with ACZ (250 mg/day) and potassium (24 mEq/day) was started at a University hospital on January 6, 2000. On the day following the first administration of ACZ,he noticed mild muscle weakness. A moderate paralytic attack occurred on January 25. ACZwas gradually increased to 750 mg/day until February 25. The severity and the frequency of paralytic attacks were impaired. Mild or moderate weakness occurred twice per week. He had ACZ(750 mg/day) and habitual breakfast at 6 AMon March 6. A severe episode of muscle weakness presented at 8 AM.He was admitted to our department at 9 AM.There was no family history of HypoPP orDM. His height was 171.0 cm and body weight was 79.8 kg. Body mass index was 27.3 kg/mm2 (normal<24.9). Other physical examination findings were normal. Neurological examination revealed muscle weakness in the four extremities, predominantly in the proximal limbs. Using Medical Research Council scale, muscle strength was: 1/5 in the iliopsoas, quadriceps and hamstring muscles; 2/5 in the deltoid, pectoralis major, anterior tibialis and gastrocnemius muscles; and 3/5 in the biceps, triceps, wrist extensor and wrist flexor muscles. Respiratory muscles were intact. The grip strength was 5 kg (left) and 3 kg (right). Muscle tenderness and swelling presented in the extremities. Muscle tone was markedly reduced. Muscle stretch reflexes were decreased without Babinski's signs. Percussioninduced moundingphenomenonand myotonia were absent. Cranial nerves, sensory and cerebellar function were normal. Before potassium administration, the first laboratory studies were performed at 3.5 hours following the final treatment with ACZ. Prominent hypokalemia and hyperinsulinemia were revealed. Serumconcentrations of chloride, glucose and creatine kinase were elevated. Arterial blood gas analysis revealed metabolic acidosis. Urinary pH and potassium levels were markedly reduced. Urinary bicarbonate concentrations were increased (Table 1) . Arterial and venous levels of potassium, insulin and glucose were measured across the forearm during the episode of weakness. Blood samples were simultaneously obtained from the right brachial artery and antecubital vein. Twoarterial and venoussamples weretaken without the use of a tourniquet. Venouspotassium concentrations were muchlower than arterial potassium concentrations. Insulin concentrations did not differ between venous and arterial samples ( Table 1) . Arterial-venous differences of glucose and potassium concentrations were markedly increased (Table 2) . Oral administration of potassium chloride (5.0 g) ameliorated quadriparesis
rapidly. Laboratory studies were performed at fasting condition on March 7 (24 hours after the last administration ofACZ: 6 AM). Arterial blood gas analysis and serum concentrations of potassium, chloride and insulin returned to normal ranges. Urinary pH, potassium and bicarbonate levels were also normal (Table 1) . Arterial-venous differences of glucose and potassium levels were reduced to normal ranges during the recovery time. Under normal condition, fasting serum glucose and blood hemoglobin A le levels were mildly increased to 1 20-130 mg/dl and 6.2% (normal<5.8), respectively. Glucose tolerance test was not performed. Other endocrine and renal function were normal. Immunological analyses, including anti-insulin antibodies, werenegative. Electrocardiogramand its monitoring were not changed between the episode and recovery of muscle weakness. Bone X-rays disclosed no osteomalacia. Muscle biopsy was undertaken from the left quadriceps muscle during attack-free intervals 4 years ago. The histopathological study exhibited a few ragged red fibers, ringed fibers and small angular fibers. There were no abnormal sizes or distribution of type I and II muscle fibers. Our results suggested mild DM, hyperinsulinemia and proximal renal tubular acidosis. The repeated laboratory data showed no proximal or distal renal tubular acidosis following ACZcessation. Triamterene (150 mg/day) was administered orally on March 12, 2000. Afterwards, the frequency and the severity of paralysis were improved dramatically. He had no severe or moderate episodes of muscle weakness for 2 years.
Discussion
ACZis often utilized as a prophylactic drug for HypoPP attacks. Dichlorphenamide, a more potent carbonic anhydrase inhibitor, has been given to patients with HypoPP and primary PP in an attempt to prevent attacks of weakness. The clinical trial excludes patients who have a history of worsening symptomsafter medicationof other carbonic anhydraseinhibitors (7) . While ACZtreatment is effective in many patients, this drug precipitated HypoPP attacks and caused hypokalemia, hyperinsulinemia and proximal renal tubular acidosis in our patient. Carbonic anhydrase is localized in the endothelium of muscle capillaries and the muscle membrane (8) . ACZ may act directly on muscle membraneof the skeletal muscle via this enzyme (9) . The prophylactic effect ofACZ on HypoPP could be related to metabolic acidosis (10), the decline of serum glucose and insulin concentrations during paralytic attacks ( 1) and the non-acidosis-dependent alternation of the muscle membrane ( 1 1). The degree ofACZ-induced metabolic acidosis is similar between patients that improved and worsened with the drug (2, 4) . Previous reports describe that ACZ-induced weakness is associated with potassium loss, DM, a variant form of HypoPPor therapeutic effects of triamterene (3- DM,hyperinsulinemia, proximal renal tubular acidosis and benefits of triamterene. The first commonhallmark points out that ACZproduces mild to severe HypoPPattacks within three days after the initial administration of this drug in all patients (3) (4) (5) , including our patient. After HypoPP patients receive the first treatment with ACZ,we should evaluate the degree and the frequency of their attacks cautiously. It is of interest that triamterene administration dramatically inhibited paralytic attacks in most of the previous cases (3-5) and in our patient. Triamterene, an aldosterone antagonist, is sometimesused for the prevention of HypoPPattacks. In a family with ACZ-induced exacerbation of HypoPP, this drug increases serum potassium levels. Triamterene administration attenuates hyperglycemia and hypokalemia in the intravenous glucose-insulin loading test (4) . The metabolic mechanism of potassium, glucose and insulin differs obviously between triamterene and ACZ treatment in patients with ACZ-induced HypoPP. Triamterene is probably the best prophylactic drug in those patients. Another commonaspect was proposed that ACZ-inducedHypoPP attacks could contribute to latent or mild DMand hyperinsulinemia, like our patient (4) . In previous studies of oral glucose tolerance and ACZstress tests, ACZenhances glucose uptake and suppresses potassium uptake across forearm muscles in normal subjects. Venous insulin levels are reduced slightly in ACZ-treated normal subjects (1 1). In contrast, our arterialvenous analyses indicated that ACZtriggered conspicuous hyperinsulinemia and prompted potassium transport from blood to skeletal muscles in the present patient. Markedreduction of urinary potassium was detected during the paralysis in our patient. The remarkable decrease of venous potassium levels maybe implicated in both direct effects ofACZon muscle membranes and proximal renal tubular acidosis due to ACZ. Our data support the possibility that this agent generates paroxysmal augmentation of insulin secretion and can potentiate potassium uptake into skeletal muscles in ACZ-induced HypoPP patients. Electrophysiological studies suggest that insulin diminishes inward rectifier potassium ion current and amplifies depolarization of HypoPPmuscle fibers (12) . DMand hyperinsulinemia might play an important role in the pathogenesis of HypoPP exacerbation due to ACZadministration. Thus, ACZ therapy should be carefully interpreted in HypoPPpatients who have hyperinsulinemia and DM.Further studies of genetic and environmental factors are needed to elucidate the precise mechanism of ACZ-induced paralysis in HypoPPpatients. We are currently analyzing HypoPPgene in our patient.
